{"groups":[{"description":"Participants received blinded treatment of vimseltinib 30 milligrams (mg) twice a week (BIW) for 24 weeks in Part 1 and open-label vimseltinib 30 mg BIW in Part 2 until end of treatment (EoT).","id":"FG000","title":"Part 1/Part 2: Vimseltinib/Vimseltinib"},{"description":"Participants received blinded treatment of matching placebo BIW for 24 weeks in Part 1 and open-label vimseltinib 30 mg BIW in Part 2 until EoT.","id":"FG001","title":"Part 1/Part 2: Placebo/Vimseltinib"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Subsequent TGCT therapy and/or surgery"},{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Other reasons"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Ongoing in study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"83"},{"groupId":"FG001","numSubjects":"40"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"83"},{"groupId":"FG001","numSubjects":"39"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"75"},{"groupId":"FG001","numSubjects":"35"}],"comment":"One participant was continuing in Part 1 of study at time of primary endpoint analysis.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"5"}],"type":"NOT COMPLETED"}],"title":"Part 1: Double Blind (Weeks 1 - 24)"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"73"},{"groupId":"FG001","numSubjects":"32"}],"type":"Ongoing in study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"35"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"35"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"74"},{"groupId":"FG001","numSubjects":"35"}],"type":"NOT COMPLETED"}],"title":"Part 2: Open Label (Weeks 25 - EoS)"}],"preAssignmentDetails":"Presented here is data from the Week 25 primary endpoint analysis. The study is ongoing."}